Eli Lilly has partnered with the National Center for Cardiovascular Diseases (NCCD) in China to promote scientific understanding and care for patients with type 2 diabetes and related disorders, including cardiovascular disease (CVD).

The collaboration will see four strategic initiatives, comprising assessment of the health economic consequences of diabetes in the country and examination of patient samples to detect new biomarkers for progression of diabetes, diabetic kidney diseases (DKD) and CVD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition, the partners will focus on developing a CVD risk calculator aimed at enhancing screening and disease management at the primary care level.

They will also create and distribute medical education for healthcare professionals involved in the treatment of diabetes-related CVD in China.

NCCD assistant director Lixin Jiang said: “As the number of people living with diabetes continues to grow rapidly throughout China, it is imperative that we address the human and economic impact of the condition.

“Our hope is this collaboration will produce learning and tools that will benefit people living with type 2 diabetes in China and elsewhere around the world.”

“Diabetes often leads to complications, including cardiovascular disease. By advancing our understanding of diabetes and cardiovascular disease, we have an opportunity to significantly improve care for people in China.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lilly and NCCD will utilise data from the patient-centred Evaluative Assessment of Cardiac Events (PEACE) Million Persons Project designed as an epidemiological screening programme in the country.

It is estimated that the project can provide access to data from more than one million people with type 2 diabetes and increased risk for CVD.

Lilly scholar Robert Heine said: “Our hope is this collaboration will produce learning and tools that will benefit people living with type 2 diabetes in China and elsewhere around the world.”

Statistics indicate growth of diabetes patients in China from more than 1% of the population in 1980 to about 11% in 2017, which also led to a rise in related complications.